The Madras High Court's ruling in *Novartis AG v. Venkata Narayana Active Ingredients* scrutinizes the evidentiary requirements necessary for the Bolar exemption in the pharmaceutical context, marking a significant development.
Analysing Bolar Exemption in Novartis AG Ruling
The Madras High Court’s decision in Novartis AG v. Venkata Narayana Active Ingredients is a landmark ruling that reviews the evidentiary criteria for invoking the Bolar exemption, particularly regarding exports for regulatory approval.
This judgment seeks to clarify the evidentiary burden laid upon manufacturers, highlighting the need for sufficient proof to utilize the Section 107A defense effectively. The approach creates a potentially more rigorous standard that may challenge pharmaceutical innovation.
Legal practitioners in the pharmaceutical sector should evaluate how this decision may affect strategies related to patent applications for generics, particularly concerning regulatory compliance and market entry issues.
Citations
- Novartis AG v. Venkata Narayana Active Ingredients (2026) 1 Madras Reporter 5
